ALLO

Allogene Therapeutics, Inc. (ALLO) - Q3 2024 10-Q Summary

Business Context and Reporting Period

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic ("off-the-shelf") T cell product candidates for cancer and autoimmune diseases. This report covers the quarterly period ended September 30, 2024. The company remains in a pre-revenue stage, with operations focused on advancing its core pipeline, including cema-cel (ALLO-501A) for large B-cell lymphoma and ALLO-316 for renal cell carcinoma.

Key Financial Metrics

Note: Cash and investments of $403.4 million as of September 30, 2024, includes $51.2M in cash equivalents, $240.3M in short-term investments, and $111.8M in long-term investments.

Material Changes vs. Prior Period

• Impairment Charges: The company recorded a significant non-cash impairment of long-lived assets of $10.7 million in Q3 2024 ($15.7M for the nine months), compared to zero in the prior year periods. This was driven by the decision to sublease portions of its South San Francisco facilities, resulting in revised fair value estimates for right-of-use assets and leasehold improvements.
• Operating Expenses: Total operating expenses increased by 14% in Q3 2024 compared to Q3 2023, primarily due to the impairment charge. Excluding impairment, operating expenses decreased due to a 22% workforce reduction implemented in January 2024, which lowered personnel costs by $6.5 million in the quarter.
• Capital Raise: In May 2024, the company completed a registered offering, issuing approximately 37.9 million shares for net proceeds of $105.3 million. This contrasts with the prior year period which relied more heavily on At-The-Market (ATM) offerings.
• Interest Income: Interest and other income increased to $6.7 million in Q3 2024 from $6.2 million in Q3 2023, driven by higher yields on the company's investment portfolio.

Guidance, Outlook, and Risks

• Clinical Progress:
  • cema-cel: The pivotal Phase 2 ALPHA3 trial for first-line large B-cell lymphoma is ongoing with nearly 30 sites activated. Enrollment is expected to complete in the first half of 2026, with data readouts expected in late 2026 and a BLA submission targeted for 2027.
  • ALLO-316: Received Regenerative Medicine Advanced Therapy (RMAT) designation for renal cell carcinoma. Phase 1 data showed a 50% best overall response rate in patients with high CD70 expression. A Phase 1b expansion cohort is ongoing.
  • ALLO-329: An autoimmune disease candidate targeting CD19 and CD70 is expected to initiate Phase 1 trials in mid-2025.
• Liquidity: Management expects cash and investments to be sufficient to fund operations for at least the next 12 months from the filing date (into 2026). The company anticipates continuing to incur net losses and will need to raise additional capital in the future.
• Internal Controls: The company identified a material weakness in internal control over financial reporting related to the technical accounting analysis of significant non-routine transactions (specifically regarding the Allogene Overland joint venture). Remediation efforts are ongoing.
• Strategic Partnerships: In May 2024, the company amended its agreement with Servier, expanding the licensed territory for CD19 products to include the European Union and the United Kingdom, potentially increasing the market opportunity by over 50%.

Investor Verification Checklist

• Runway Validation: Verify the sufficiency of the $403.4M cash position against the projected burn rate, considering the $15.7M impairment charge and ongoing clinical trial costs.
• Impairment Details: Review the specific assumptions used in the discounted cash flow analysis for the sublease impairments to understand the impact on future facility costs.
• Internal Control Remediation: Monitor the status of the remediation plan for the material weakness in internal controls to ensure future financial reporting reliability.
• ALPHA3 Trial Enrollment: Track enrollment rates for the ALPHA3 trial, as the company anticipates a high screen failure rate due to the requirement for Minimal Residual Disease (MRD) positivity.
• Partnership Stability: Assess the risks associated with the Servier and Cellectis agreements, particularly given the ongoing arbitration between Servier and Cellectis regarding the Servier-Cellectis Agreement.